MANNKIND CORP (MNKD) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 52.93M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $52.93M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $52.83M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $74.88M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $127.39M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $57.01M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $47.31M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $46.34M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $62.37M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $96.64M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $193.27M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $238.48M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $83.02M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $86.18M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $85.87M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $69.77M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $54.31M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $35.51M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $67.24M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $124.18M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $51.74M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $62.52M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $247.83M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $67.00M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $52.40M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $63.22M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $38.87M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $29.91M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $30.17M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $7.97M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $34.53M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $71.16M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $10.45M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $26.18M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $26.71M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $43.95M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $20.09M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $43.38M | (m) | (m) |
| 2017-03-31 | (m) | (m) | $47.98M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $22.89M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $35.53M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $63.73M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $27.65M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $59.07M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $32.93M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $107.19M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $120.84M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $120.84M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $172.47M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $41.21M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $35.76M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $70.79M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $93.80M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $28.53M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $28.00M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $61.84M | (m) | (m) |
| 2012-09-30 | $2.12M | (m) | $1.76M | $350.00K | (m) |
| 2012-06-30 | $31.99M | (m) | $31.64M | $350.00K | (m) |
| 2012-03-31 | $56.70M | (m) | $56.35M | $350.00K | (m) |
| 2011-12-31 | $3.20M | (m) | $2.68M | $515.00K | (m) |
| 2011-09-30 | $23.30M | (m) | $22.79M | $513.00K | (m) |
| 2011-06-30 | $25.27M | (m) | $24.77M | $497.00K | (m) |
| 2011-03-31 | (m) | (m) | $46.91M | (m) | (m) |
| 2010-12-31 | $70.43M | (m) | $66.06M | $4.37M | (m) |
| 2010-09-30 | (m) | (m) | $97.93M | (m) | (m) |
| 2010-06-30 | (m) | (m) | $28.36M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $30.02M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $27.65M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |